[MeMed in EIN Newswire] MeMed awarded US BARDA contract to demonstrate clinical utility of the FDA-cleared MeMed BV® test for distinguishing bacterial from viral infections

/EIN News/ — TIRAT CARMEL, Israel; BOSTON, MA – 24 October, 2023 – MeMed, a leader in host response technologies, is pleased to announce that it has been awarded a contract valued at $727,799 by the Division of Research, Innovation, and Ventures (DRIVe) of the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA). The contract will support the execution of a randomized controlled trial designed to build on existing clinical utility data demonstrating that MeMed BV can improve patient outcomes.

Read more here.